{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancer+Metastatic&page=20", "query": { "condition": "Gastrointestinal Cancer Metastatic", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 2359, "total_pages": 236, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancer+Metastatic&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancer+Metastatic&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T18:13:32.506Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00931840", "title": "A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "EZN-2208, Cetuximab and Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enzon Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2009-06", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2011-09-20", "last_synced_at": "2026-11-15T18:13:32.506Z", "location_count": 35, "location_summary": "Tucson, Arizona • Alhambra, California • Bakersfield, California + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00931840" }, { "nct_id": "NCT01576666", "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dose Escalation", "Safety", "Preliminary Efficacy", "Advanced Solid Tumors", "Metastatic Breast Cancer", "Advanced Pancreatic Adenocarcinoma", "Metastatic Colorectal Cancer", "Recurrent Glioblastoma Multiforme", "Gastric Cancer", "Gastroesophageal Junction Cancer", "Triple Negative Metastatic Breast Cancer", "Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer" ], "interventions": [ { "name": "LDE225", "type": "DRUG" }, { "name": "BKM120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2012-07", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-11-15T18:13:32.506Z", "location_count": 13, "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01576666" }, { "nct_id": "NCT05238922", "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB0123667", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 291, "start_date": "2022-07-05", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-11-15T18:13:32.506Z", "location_count": 18, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05238922" }, { "nct_id": "NCT00398879", "title": "Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer" ], "interventions": [ { "name": "Perifosine", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Perifosine Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AEterna Zentaris", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 381, "start_date": "2005-08", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2018-03-14", "last_synced_at": "2026-11-15T18:13:32.506Z", "location_count": 49, "location_summary": "Tucson, Arizona • Beverly Hills, California • Deer Park, California + 45 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Deer Park", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00398879" }, { "nct_id": "NCT03373188", "title": "VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colon Carcinoma Metastatic in the Liver", "Colorectal Adenocarcinoma", "Pancreatic Adenocarcinoma", "Resectable Pancreatic Carcinoma", "Stage I Pancreatic Cancer", "Stage IA Pancreatic Cancer", "Stage IB Pancreatic Cancer", "Stage II Pancreatic Cancer", "Stage IIA Pancreatic Cancer", "Stage IIB Pancreatic Cancer", "Stage III Pancreatic Cancer", "Stage IV Colorectal Cancer", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer" ], "interventions": [ { "name": "Anti-SEMA4D Monoclonal Antibody VX15/2503", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2017-12-15", "completion_date": "2021-10-28", "has_results": false, "last_update_posted_date": "2024-03-20", "last_synced_at": "2026-11-15T18:13:32.506Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Rochester, New York", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03373188" }, { "nct_id": "NCT01545141", "title": "Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Colorectal Carcinoma", "Colorectal Tumors", "Neoplasms, Colorectal" ], "interventions": [ { "name": "Chemokin Modulatory Regimen (5 MU/m2)", "type": "DRUG" }, { "name": "Chemokin Modulatory Regimen (10 MU/m2)", "type": "DRUG" }, { "name": "Chemokin Modulatory Regimen (20 MU/m2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2012-10", "completion_date": "2017-04-08", "has_results": true, "last_update_posted_date": "2023-10-27", "last_synced_at": "2026-11-15T18:13:32.506Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01545141" }, { "nct_id": "NCT00976170", "title": "Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "GC33(RO5137382)", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chugai Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2009-09", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2014-10-03", "last_synced_at": "2026-11-15T18:13:32.506Z", "location_count": 5, "location_summary": "San Francisco, California • Miami, Florida • New York, New York + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00976170" }, { "nct_id": "NCT07224841", "title": "Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "CRC (Colorectal Cancer)" ], "interventions": [ { "name": "cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase)", "type": "DIAGNOSTIC_TEST" }, { "name": "EpiDRIVE Assay (Targeted Sequencing / qPCR Validation)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2024-06-21", "completion_date": "2028-06-18", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-11-15T18:13:32.506Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224841" }, { "nct_id": "NCT03146962", "title": "High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Pancreatic Cancer", "Lung Cancer" ], "interventions": [ { "name": "Vitamin C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2017-03-29", "completion_date": "2023-04-21", "has_results": true, "last_update_posted_date": "2024-05-02", "last_synced_at": "2026-11-15T18:13:32.506Z", "location_count": 2, "location_summary": "Brooklyn, New York • New York, New York", "locations": [ { "city": "Brooklyn", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03146962" }, { "nct_id": "NCT01186705", "title": "Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer", "Rectal Cancer" ], "interventions": [ { "name": "MK-2206", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2010-08", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2015-11-18", "last_synced_at": "2026-11-15T18:13:32.506Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01186705" } ] }